Evidence map›Paper›PMID 34149934›Full record

ArticleJournal of Cancer2021

MicroRNA-455-5p Contributes to Cholangiocarcinoma Growth and Mediates Galangin's Anti-Tumor Effects.

Xu Deng, Meiling Zuo, Zhifang Pei, Yuanlin Xie, Zhongbao Yang, Zhihui Zhang, Minna Jiang, Dabin Kuang

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Rapid assessment of Opisthorchis viverrini IgG antibody in serum: A potential diagnostic biomarker to predict risk of cholangiocarcinoma in regions endemic for opisthorchiasis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xu DengDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Meiling ZuoDepartment of Pharmacy, The Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan, China.
Zhifang PeiDepartment of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuanlin XieDepartment of Pharmacy, The Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan, China.
Zhongbao YangDepartment of Pharmacy, The Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan, China.
Zhihui ZhangDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Minna JiangDepartment of Cardiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Dabin KuangDepartment of Pharmacy, The Affiliated Changsha Hospital of Hunan Normal University, Changsha, Hunan, China.
Third Xiangya Hospital · CNCentral South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fully understanding the mechanism of how Cholangiocarcinoma (CCA) development and discovering promising therapeutic drugs are important to improve patients' survival time. This study identifies that microRNA-455-5p (miR-455-5p) targets protein phosphatase 1 regulatory subunit 12A (PPP1R12A), an effect that represses mitogen-activated protein kinase (MAPK) and PI3K/AKT pathway activation, thereby controlling CCA cells survival and metastasis. Moreover, miR-455-5p expression is reduced in CCA tissues and negative correlation with PPP1R12A and PPP1R12A knockdown phenotypic mimics miR-455-5p' effects on CCA cells. Furthermore, we demonstrate that galangin inhibits CCA growth both

Indexed as

cholangiocarcinomagalanginmetastasismicroRNAsurvival

Identifiers

PMID34149934
PMCPMC8210562
OpenAlexW3173813935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.